Evotec
Hans-Ulrich Wolf has an extensive work experience in the field of Information Technology (IT) and logistics. Hans-Ulrich currently holds the position of Chief Information Officer (CIO) at Evotec since July 2022. Prior to that, they served as the Executive Vice President and Global Head of IT at Evotec starting from May 2019. Before joining Evotec, they worked at FIEGE as the CIO of Fiege Group from January 2012 to April 2019. Hans-Ulrich also held the position of Global CIO at Hermes Europe from March 2009 to December 2011. Hans-Ulrich Wolf has also worked at Hermes Logistics Group as a Division Manager in Corporate Planning, IT, and Projects from 2004 to 2008. Hans-Ulrich served as the Vice President of IT and Logistics at Sumisho Hermes General Service Inc. from February 2002 to September 2004. At Hermedis GmbH, they were the Head of IT from June 2001 to January 2002. Prior to their corporate roles, Hans-Ulrich Wolf had a career in the German Armed Forces as a Lieutenant from October 1985 to September 1987.
Hans-Ulrich Wolf earned a Master's degree in Computer Science from the University Hildesheim, where they studied from 1989 to 1995.
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.